{"id":"W4415942672","doi":"10.1016/j.annonc.2025.08.3008","title":"2392P PCPro as a prognostic plasma lipidomic biomarker in TheraP (ANZUP 1603): A randomised trial of [177Lu]Lu-PSMA-617 (LuPSMA) vs cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Cancer Australia; Prostate Cancer Foundation of Australia; Australian Nuclear Science and Technology Organisation; Prostate Cancer Foundation","keywords":"Cabazitaxel; Prostate cancer; Androgen receptor; Biomarker; Progression-free survival; Overall survival; Abiraterone; Androgen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001414412,0.001966108,0.003086208,0.000494201,0.0004122778,0.001802183,0.001087603,0.002206369,0.009933899],"category_scores_gemma":[0.001256502,0.0009904592,0.002010028,0.0005629409,0.001546509,0.001588468,0.0007350353,0.004819993,0.001817488],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001082089,"about_ca_system_score_gemma":0.001379051,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001743164,"about_ca_topic_score_gemma":0.003056003,"domain_scores_codex":[0.9992526,0.000366271,0.00003786648,0.0001361774,0.00004824168,0.0001587455],"domain_scores_gemma":[0.9994677,0.0001036012,0.00009631412,0.0000575755,0.00003046933,0.000244374],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9845184,0.002019576,0.0002905509,0.0001996976,0.0006560078,0.00002568781,0.00002402054,0.0002612803,0.002384863,0.0001380037,0.0004741935,0.00900764],"study_design_scores_gemma":[0.9463905,0.04985685,0.001228245,0.00002378339,0.0006641592,0.00003076919,0.00002249027,0.0003676093,0.0004873628,0.0001801723,0.0007255918,0.00002250194],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986692,0.004046534,0.000638076,0.001392913,0.000844267,0.001842806,0.001257968,0.0002005363,0.003084765],"genre_scores_gemma":[0.9874086,0.002323502,0.00101086,0.001054385,0.0005081965,0.001778068,0.001454397,0.00005564617,0.004406248],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009933899,"threshold_uncertainty_score":0.03323215,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09464686932957608,"score_gpt":0.4401653355578007,"score_spread":0.3455184662282246,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}